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Abstract: Non-natural terpenoids offer potential as pharma-
ceuticals and agrochemicals. However, their chemical 
syntheses are often long, complex, and not easily amenable to 
large-scale production. Herein, we report a modular 
chemoenzymatic approach to synthesize terpene analogues 
from diphosphory-lated precursors produced in quantitative 
yields. Through the addition of prenyl transferases, farnesyl 
diphosphates, (2E,6E)-FDP and (2Z,6Z)-FDP, were isolated in 
greater than 80 % yields. The synthesis of 14,15-dimethyl-FDP, 
12-methyl-FDP, 12-hydroxy-FDP, homo-FDP, and 15-methyl-
FDP was also achieved. These modified diphosphates were 
used with terpene synthases to produce the unnatural sesqui-
terpenoid semiochemicals (S)-14,15-dimethylgermacrene D 
and (S)-12-methylgermacrene D as well as dihydroartemisinic 
aldehyde. This approach is applicable to the synthesis of many 
non-natural terpenoids, offering a scalable route free from 
repeated chain extensions and capricious chemical phosphor-
ylation reactions.  
Terpenoid natural products are highly diverse secondary 
metabolites with economic importance in fields as diverse as 










 and agrochemicals (farnesenes).
[8]
 All known 
terpenes are produced from two universal five-carbon precursors, 
dimethylallyl diphosphate (DMADP, 1) and isopentenyl 
diphosphate (IDP, 2), which are derived from either the 
mevalonate (MVA) or non-mevalonate (1-deoxy-d-xylulose-5-
phosphate, DXP) pathways (Supporting Infor-mation, Scheme 
S1). As precursors to many useful chemicals, significant efforts 
have been made to upregulate production of 1 and 2 in vivo for 
terpene biosynthesis.
[3, 9–14]
 While high terpene yields can be 
achieved, most notably for amorpha-4,11-diene by yeast 
fermentation for the production of the anti-malarial artemisinin,
[3, 
15]
 efficient production often requires significant metabolic 
engineering and fine-tuning.[16–18]  
The synthesis of products beyond the natural terpenome 
offers the possibility of improved chemical properties and altered 
biological activities. Analogues of terpene synthase substrates 
have been pivotal to determining the mechanisms of terpene 
cyclizations by establishing the sequence of  
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carbocation migrations, hydride and methyl shifts and the 
position of any proton eliminations.
[19–22]
 These analogues can 
often act as substrates, forming modified terpene prod-ucts.
[22–25]
 
Point mutations of terpene synthases can dramat-ically alter 
product distributions, catalytic efficiencies, and substrate 
preferences allowing access to a plethora of new, non-natural 
terpenoid products.
[26–29]
 For example, in addition to farnesyl 
diphosphate (FDP), (S)-germacrene D synthase (ScGDS) accepts 
14,15-dimethyl-FDP as a substrate and cyclizes it to (S)-14,15-
dimethylgermacrene D. Strikingly, while the natural product (S)-
germacrene D is a repellent of aphids, (S)-14,15-
dimethylgermacrene D acts as an attrac-tant.
[30, 31]
 Similarly, 12-
hydroxy-FDP is an alternative sub-strate for amorpha-4,11-diene 
synthase (AaADS), which forms dihydroartemisinic aldehyde, 
thereby reducing the subsequent number of chemical steps 
needed for the synthesis of artemisinin.
[32] 
 
The chemistry used to synthesise modified geranyl- (GDP, 
C10), farnesyl- (FDP, C15) and geranylgeranyl- (GGDP, C20) 
diphosphates is often unsuitable for the large-scale produc-tion 
required for many applications, for instance in crop protection or 
medicinal therapy. Analogues are commonly derived by iterative 
chain extensions using enolate and Wittig chemistry, often 
suffering from low yields and requiring repeated 
chromatography.
[31–35]
 The final step is generally addition of the 
diphosphate group by substitution of a halo-genated allylic 
alcohol with tris(tetra-n-butylammonium) hydrogen diphosphate. 
This step requires multiple ion exchange procedures and results 
in highly variable yields (10–60 %).
[38]
 To address these 
challenges, we designed a modular chemoenzymatic synthesis to 
generate terpene analogues from modified IDP and DMADP 
intermediates. We envisioned using promiscuous kinases to 
diphosphorylate prenol (3) and isoprenol (4), and then adding 
prenyl trans-ferases and terpene cyclases to create a complete 
enzymatic pathway to synthesize terpenes directly from prenols. 
The natural promiscuity of the kinases, prenyl transferases, and 
terpene cyclases constituting this truncated pathway should then 
allow for the use of modified prenols as substrates. Sequential use 
of different prenyl transferases would enable modular 
chemoenzymatic assembly of isoprenoids with unprecedented 
ease of placement of functional groups and access to synthetic 
space not naturally available or limited to more difficult post-
cyclisation tailoring reactions (P450 oxi-dation, S-adenosyl-l-
methionione-dependent methyla-tion).[39, 40] 
  
The natural substrate of the Escherichia coli hydroxye-
thylthiazole kinase (EcTHIM) is 5-(2-hydroxyethyl)-4-meth-
ylthiazole, but EcTHIM has also been reported to phosphyor-
ylate 3.[41] We speculated that by combining EcTHIM with the 






jannaschii (MjIPK) both 1 and 2 could be synthesized directly 
from their respective alcohols (Figure 1 a). Compared to natural 
biosynthetic pathways (Supporting Information, Scheme S1), the 
number of enzymatic steps and equivalents of energy-rich 
molecules, such as ATP, CTP, and NADPH, is reduced. 
Crucially, this more straightforward synthetic route should also 
allow greater substrate variation. Efficient phosphorylation of 3 
and 4 by EcTHIM was found to be possible using phosphoenol 
pyruvate (PEP) in the presence of pyruvate kinase to recycle a 
catalytic quantity of ATP and to prevent significant ATP 
hydrolysis. After optimising the relative concentrations of PEP 
and substrates to minimize inhibition of EcTHIM by PEP 
(Supporting Information, Figure S2), this system generated 





H NMR and LC-MS (Figure 1 b and 
Supporting Information, Figures S1–S4). 
 











































Figure 1. a) Stepwise ATP-dependent monophosphorylation of prenol 
(3) and isoprenol (4) by EcTHIM (PDB: 1EKK) and diphosphorylation 
of 5 and 6 by MjIPK (PDB: 3K4Y) to form dimethylallyl diphosphate 
(DMADP, 1) and isopentenyl diphosphate (IDP, 2). b) 31P NMR time-
course following i) monophosphorylation of 4 to 6 (d 3.7) by EcTHIM 
and ii) phosphorylation of 6 to 2 (d 5.9, 10.0) by MjIPK. Phosphoe-nol 
pyruvate (PEP, d 0.5) is used to recycle catalytic quantities of ATP. c) 
Analogues of 3 and 4 tested with EcTHIM. 
 
substrate scope of EcTHIM. A variety of substrates with 
structural similarity to 3 and 4 featuring methylated, deme-
thylated, and hydroxylated substrates, and increased chain lengths 
were tested (Figure 1 c and Supporting Information, Figures S5–
S7). For substrates where the phosphorylation rate was 
significantly higher than the background rate of ATP hydrolysis, 
kinetic parameters were determined by a coupled assay with 
lactate dehydrogenase and spectroscopically monitoring 
consumption of NADH (Supporting Information, Figure S8 and 
Table S1). EcTHIM was found to turn over 4 with an 
approximately 10-fold greater kcat than was measured for 3. 
Exploring the substrate scope established a maximum accepted 
chain length of seven carbons (Figure 1 c and Supporting 
Information, Figure S8 and Table S1). Those substrate affinities 
that could be measured were all compa-rable, suggesting that 
EcTHIM s promiscuity arises from weak non-specific contacts 
with its substrates. All products from reactions with EcTHIM 
were accepted as substrates by MjIPK; the resulting diphosphates 




P NMR and LC-MS (Supporting 
Information, Figur-es S6 and S7 and Table S2).
[42] 
 
Synthesis of (2E,6E)-FDP (7) was achieved using a 1:2 ratio 
of 3 to 4, EcTHIM, MjIPK, and the (2E,6E)-FDP synthase from 
Geobacillus stearothermophilus (GsFDPS, Scheme 1 a). In 
the presence of magnesium (5 mm), a neces-sary cofactor for the 
enzymes (Supporting Information, Figures S9 and S10), 7 
precipitated from solution. Purification of 7 was achieved by 
repeatedly washing the precipitate with water to remove any 
impurities before addition of excess inorganic diphosphate to 
coordinate the magnesium, disrupt-ing the FDP-Mg
2+
 complex. 
Once soluble, 7 was purified using a C18 reverse phase column to 
give an isolated yield of 83 %. 
 
Replacing GsFDPS with (2Z,6Z)-FDP synthase from 
Solanum habrochaites, allowed ready access to (2Z,6Z)-FDP 
(8) in 92 % yield (Supporting Information, Figure S11), avoiding 
the cumbersome synthesis, and losses during diphos-phorylation 
of isomerically pure (2Z,6Z)-farnesol. When 1 was present in 
large excess over 2, GDP (9) was formed using GsFDPS 
(Supporting Information, Figure S12). Unlike FDPs, 9 is soluble 
in the presence of magnesium and was separated from FDP by 
filtration. Using the Y81M variant of GsFDPS, allowed GGDP 
(10) to be generated from a 1:3 ratio of 1 and 2 (Supporting 
Information, Figure S11).
[43]
 When methylated or hydroxylated 
analogues of 2 were combined with 1 in the presence of 
GsFDPS, 15, 16, and 17 were produced (Scheme 1 b and 
Supporting Information, Figures S13–S15). As with FDP, the 
products precipitated from the reaction mixture in the presence of 
magnesium allowing their straightforward isolation and 
purification. To access terpene precursors derived from both 2 
and analogues thereof without forming statistical mixtures of 
products, 9 was mixed with methyl-IDP in the presence of 
GsFDPS to synthesise 15-methyl-FDP (18, Supporting 
Information, Fig-ure S16). Similarly, when homoisoprenol (14) 
was diphos-phorylated and added to 9, homo-FDP (19) was 
produced (Supporting Information, Figure S17), although in this 
case the reaction progressed extremely slowly, most likely 








































Scheme 1. a) Pathway for the synthesis of GDP (9), (2E,6E)-FDP 
(7), (2Z,6Z)-FDP (8), and GGDP (10). b) FDP analogues 12-
hydroxy-FDP (15), 12-methyl-FDP (16), 14,15-dimethyl-FDP (17), 
15-methyl-FDP (18), homo-FDP (19), enzymatically synthesized 
from prenol (3), isoprenol (4), 4-hydroxyprenol (11), methylprenol 
(12), methylisoprenol (13), and homoisoprenol (14). 
 
 
Finally, terpene synthases were added to reaction mix-tures to 
produce high-value sesquiterpene products and unnatural 
analogues (Figure 2). To avoid precipitation of FDP or its 
analogues by the presence of magnesium, 2-hydroxypropyl-b-
cyclodextrin equimolar to the FDP product was added 
(Supporting Information, Figure S9). The hydro-phobic interior of 
the cyclodextrin acts as a host, preventing guest FDP molecules 
from interacting with each other and forming larger scale 
complexes (Supporting Information, Figure S18). GC-MS 
analyses of the pentane extractable products obtained from 
phosphorylation/cyclization reactions starting from 3 and 4 
catalyzed by ScGDS, AaADS, 7-epizingiberene synthase from 
Solanum habrochaites (ShEZS), and ( )-germacradiene-4-ol 
synthase from Strep-tomyces citricolor (ScGD4OL) showed 
that the respective natural products had been generated (20–23) 
(Figure 2, S19– 30).
[30, 32, 44]
 Furthermore, using methylated 
prenol ana-logues 12 and 13 directly yielded the desirable 
unnatural semiochemicals (S)-14,15-dimethylgermacrene D (24), 
(S)-12-methylgermacrene D (25), and (S)-15-methylgermacr-ene 
D (26) (Figure 2). Similarly, using 4-hydroxyprenol (11) and 4 to 
form 15 followed by addition of AaADS yielded 











































Figure 2. Synthesis of natural and unnatural sesquiterpenes from  
prenols. GC-traces of products formed under AaADS, ScGDS,  
ScGD4OLS, and ShEZS catalysis in combination with EcTHIM, MjIPK,  
an appropriate FDPS, pyruvate kinase, phosphoenol pyruvate, and  
catalytic ATP. Terpene products (*) (S)-germacrene D (20), ( )-germa-  
cradiene-4-ol (21), amorpha-4,11-diene (22), 7-epizingiberene (23), (S)-  
14,15-dimethylgermacrene D (24), (S)-12-methylgermacrene D (25),  




unknown sesquiterpene products were formed using methy-lated 
prenols and ScGD4OL or AaADS. GC-MS results were 
consistent with unnatural methylated terpenoids (Supporting 
Information, Figures S25, S26, S29, and S30).  
In summary, we report a novel, efficient modular chemo-
enzymatic synthesis of terpenes and their analogues by directly 
phosphorylating five-carbon precursors. Coupling 
phosphorylation with ATP recycling allows quantitative yields to 
be achieved for the two phosphorylation steps. Combining these 
reactions with prenyl transferases results in excellent yields 
(greater than 80 %) of natural farnesyl diphosphates, key 
intermediates in the synthesis of sesquiter-penoid natural 
products. As 3 and 4 precursors are signifi-cantly cheaper than 




petitive alternative synthesis of FDP; given the difficulty of 
synthesising (2Z,6Z)-farnesyl diphosphate, this work repre-sents 
the first feasible route to its synthesis. Purification of the products 
is straightforward due to the formation of insoluble magnesium 
complexes. Adding prenyl transferases and ter-pene synthases to 
the reaction mixture allows synthesis of natural and non-natural 
terpenes, highlighting the strength of this modular approach. 
Finally, the ease of addition in different combinations of prenol 
analogues to the synthesis, allows unprecedented access to 
modified linear terpene precursors. Importantly, this capacity to 
synthesize unnatural FDPs is a key advantage of this method over 
whole-cell procedures, where competition with natural pathways 
would be expected to result in challenges with toxicity. We 
anticipate that this new approach will allow modified terpene 
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